The IFMIF-DONES facility, currently under construction in Granada (Spain), is dedicated to testing materials under neutron irradiation, as part of advanced materials research for next-generation fusion reactors. The superconducting linear accelerator of the facility is intended to deliver a continuous-wave deuteron beam with an energy of 40 MeV and an unprecedented current of 125 mA. The production of neutrons is then achieved by driving the 5 MW beam into a liquid lithium target. Beam diagnostics play a critical role in the IFMIF-DONES accelerator due to several unique challenges. These include the extremely high beam power, the harsh environment due to neutron and gamma radiation and the required operational availability of the accelerator. Moreover, the accelerator may operate in pulsed and continuous wave for commissioning and standard operation, respectively. This work presents an overview of the main beam diagnostics techniques and strategies needed to address these challenges, as well as the construction plan and the prototyping works. ACKNOWLEDGEMENT This work has been carried out within the framework of the EUROfusion Consortium.

The IFMIF-DONES facility located at Escúzar in Spain will consist of an accelerator delivering 125 mA of 40 MeV deuterons onto a Lithium target. At the last part of the accelerator, when the beam footprint is almost shaped, different beam diagnostics are considered. In order to protect the machine against changes of the beam and give a safe interlock, a novel RF pickup made of eight electrodes is designed. This RF pickup is designed with the objective to sense displacements of the beam centroid as changes of the beam profile. In this paper a preliminary study is presented based on an analytical and CST simulation approach. Both approaches, considering pencil and real beams from TraceWin simulations, are compared. Next, a sensitivity study of how different parameters affect the response is performed in CST simulations. This work has been carried out within the framework of the EUROfusion Consortium.